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SUMMARY Despite the existence of various scientiﬁc research 
on the beneﬁcial effect of speciﬁc immunotherapy with speciﬁc 
airborne allergens in the treatment of atopic dermatitis, this 
method has not been easily accepted, as the methodology and 
the valuation of the studies were heterogeneous. Over the last 
few years, meta-analysis technology has been developed as 
a useful tool to globally value the results of different research 
trials related to one speciﬁc scientiﬁc problem. When meta-
analyses are carried out correctly, they are accepted as the 
most appropriate way to express the results obtained from 
different studies. Not many studies have been published in the 
case of atopic dermatitis and speciﬁc immunotherapy. 
 In this paper, we attempt to present and discuss results 
obtained by various authors on this topic, beginning with the 
publication of Strauss and Kligman in 1957. It should be noted 
that for patients with IgE-mediated airborne allergy, especially 
children, speciﬁc immunotherapy as an early treatment in cases 
of atopic dermatitis could have an additionally preventive nature 
in terms of protection against the development of a respiratory 
atopic problem. Speciﬁc immunotherapy should therefore be 
at least considered in the treatment of selected cases of atopic 
dermatitis patients presenting airborne IgE-mediated allergy. 
KEY WORDS: atopic dermatitis, speciﬁc immunotherapy, 
airborne allergens, IgE
INTRODUCTION
 Atopic dermatitis (AD) is deﬁned as a chronic 
and recurrent skin inﬂammatory disease. Patients 
suffering from AD with skin eczematous lesions 
as the only apparent symptom in up to 60-80% of 
cases present positive results of bronchial provo-
cation test, indicating the preclinical existence of 
minimal persistent respiratory inﬂammation (1-5). 
Therefore, AD is an atopic, inﬂammatory disease 
that may involve not only skin but also other or-
gans and systems, and it seems obvious that the 
rational therapeutic approach should be a combi-
nation of topical and systemic methods. It is also 
obvious that such a complex treatment may only 
be successful in case of a well-deﬁned and un-
derstood pathological process. Unfortunately, the 
etiopathogenesis of AD is still obscure. It is be-
lieved to be a multifactorial disease with a strong 
genetic predisposition and a wide variety of immu-
nological and non-immunological abnormalities. 
Among environmental factors, airborne allergens 
like house dust mite and plant pollen allergens as 
well as moulds and animal epithelium allergens 
seem to be of great importance for the manifesta-
tion of AD. Some authors report a high percentage 
53ACTA DERMATOVENEROLOGICA CROATICA
of positive skin prick tests and elevated antigen 
speciﬁc IgE (asIgE) serum levels directed against 
airborne allergens, especially to house dust mite 
allergens (Dermatophagoides pteronyssinus – Dp 
and Dermatophagoides farinae – Df) (6,7). Also, 
atopy patch testing (APT) with environmental al-
lergens like house dust mites may provoke ec-
zematous lesions in AD patients (8-10), inducing 
an IgE-mediated contact reaction in an extrinsic/
allergic type of the disease (11). Furthermore, a 
clear correlation has been shown between an ex-
acerbation of AD and increased exposure to house 
dust mite allergens in patients’ homes with an im-
provement of the clinical score following careful 
avoidance of these airborne allergens (12,13). A 
recent viewpoint on AD immunopathogenesis pro-
poses a biphasic cytokine expression pattern as 
a model of disease progression from early acute 
to chronic lesions (14). So it seems that IFN-γ/IL-
12 dependent Th2→Th1 switch is responsible for 
AD progression to chronic stages of the disease. 
Knowing that Th2→Th1 immune deviation due to 
upregulation of IFN-γ-producing cells (15-17) has 
been previously proposed as a mechanism of spe-
ciﬁc immunotherapy (SIT), we can conclude that 
it should be at least helpful in the treatment of se-
lected AD patients.
Allergy vaccines in the treatment of AD patients
 Allergy vaccines in selected cases of AD pa-
tients with a well-documented airborne allergy 
have been long regarded as a potential tool for 
successful control of the disease. Conventional 
speciﬁc immunotherapy (SIT), i.e. the subcutane-
ous injections of allergen extract, is known to be a 
curative treatment for special forms of IgE-medi-
ated allergies. It is particularly effective in patients 
suffering from rhinitis and asthma elicited by pol-
lens (18-23), house dust mite allergy (23-27) and 
Hymenoptera venom (28,29). SIT is the only treat-
ment that may affect the natural course of allergic 
diseases, as it may prevent the onset of new sen-
sitizations and inﬂuences the natural course of the 
atopic disease it reduces development of asthma 
in patients with allergic rhinitis (30,31). Therefore, 
SIT can also be regarded as a preventive method. 
It seems to be exceptionally important in AD pa-
tients who are at high risk of allergic respiratory 
signs and symptoms. It seems that SIT may lead 
to a noticeable clinical improvement in AD patients 
involving somehow different immunological events 
than in allergic rhinitis or bronchial asthma, and 
further clariﬁcation of this problem is obviously 
needed. 
 Nowadays, SIT is rarely used in the manage-
ment of AD, although it has been attempted in se-
lected cases over many years. In 1957, Strauss 
and Kligman were the ﬁrst to publish their data in-
dicating the possible use of SIT in the treatment of 
AD patients (32). In 1974, Kaufman and Roth (33) 
performed a controlled trial on a group of 26 pa-
tients with AD. A water-soluble alum-precipitated 
pyridine extracted complex was used in the treat-
ment of 16 patients. The composition of allergy 
vaccines was dependent on the results of skin 
testing, and respective reacting airborne antigens 
were diluted from independently prepared materi-
als so that appropriate concentrations of antigens 
were in each patient’s SIT therapy set (house dust 
mite allergens, plant pollen allergens, animal epi-
thelium allergens). The remaining 10 AD patients 
received placebo. The ﬁrst 16 doses were given at 
one-week intervals, and thereafter injections were 
given every three weeks throughout the 24-month 
study period. There was a clinical improvement 
in 13 out of 16 AD patients treated with an active 
vaccine, and 4 of 10 treated with buffered saline. 
There was a signiﬁcant difference in the clinical 
improvement between the treated group and the 
placebo group of AD patients. 
 Further investigations were conducted by Di 
Prisco, De Feuenmayer and Champion in 1979 
(34). The authors selected 15 patients from over 
3,000 cases of AD patients, aged 6-14 years with 
a mean of 25 years. The inclusion criteria were: a 
history indicating that exposure to the suspected 
aeroallergen repeatedly caused itching and an 
exacerbation of skin lesions; a positive skin prick 
test, in a few cases conﬁrmed by a RAST test; the 
aeroallergen could not be readily avoided; symp-
toms were severe enough to warrant the difﬁcul-
ties and cost of treatment; and, ﬁnally, all patients 
with the ﬁrst four essential criteria had a similar 
clinical picture. Most patients were severely af-
fected and had failed to respond to conventional 
therapy, including in-patient treatment. The most 
important aeroallergens were house dust mite – 9 
patients, and grass pollen allergens – 4 patients. 
The vaccines used were alum-precipitated pyri-
dine extracted. Signiﬁcant improvement occurred 
in 33.3% of patients, improvement in 26.7% and 
slight improvement in 40% of AD patients. Im-
provement usually started after the fourth or ﬁfth 
injection. In some cases, it lasted for only a few 
weeks, usually some months, and in a few cases 
a single course seemed to achieve an improve-
ment maintained for years. It should be stressed 
that 7 of the patients had a single course of 8 or 
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more injections at weekly intervals, 4 patients had 
repeated courses and 4 were being maintained 
on a long-term continuation course of monthly in-
jections of the maximum dose given in the initial 
standard course. It seems that surely in the last 
group of patients SIT could be the most effec-
tive. The authors concluded that SIT has a place 
in selected AD patients with a severe course of 
skin inﬂammation and can obviously be expected 
to ameliorate only the allergic component of this 
multifactorial disease. There was some additional 
research in the late 1970’s on the possible use of 
SIT in allergic skin disorders (35-37). 
 In 1982, Ring (38) presented his paper on suc-
cessful SIT in monozygotic twins with AD. Two 
sisters (monozygotic twins) suffering from severe 
AD with seasonal exacerbation during early sum-
mer were treated with either grass pollen extract 
(Alum-precipitated extract ADL) or saline. After 2 
years of treatment, the clinical score of the patient 
treated with grass pollen extract improved signiﬁ-
cantly, while the placebo caused minimal change 
in her twin. The therapeutic effect was paralleled 
by a greater decrease in total serum IgE (from 
4.200 to 1.3000 KU/l) in the pollen treated patient 
(compared with 3.500 to 2.580 KU/l) in the control 
group.
 A group of Danish investigators performed an 
evaluation of non-speciﬁc and speciﬁc immuno-
therapy in severe cases of AD (39). SIT was per-
formed in a group of 12 adult patients sensitive 
to house dust mite allergens. Three also suffered 
from asthma, 3 from rhinitis and 2 patients dis-
played all three main atopic diseases. However, 
AD was the major health problem in all patients 
and the only purpose of treatment. Six out of 12 
patients improved, 3 patients showed slight im-
provement, while 2 patients were unchanged and 
1 got worse after the observation period, which 
lasted from 1.5 to 5 years. In most cases, an initial 
increase followed by a decrease of total serum IgE 
was detected during the treatment. There was a 
similar but less pronounced decrease of asIgE se-
rum levels measured by RAST. What is important 
from the clinical standpoint is that the consumption 
of topical steroids was found to be reducing dur-
ing SIT. In the authors’ opinions, based upon their 
investigation and other reports (Ring, Kaufmann-
Roth) in the literature, it may be worthwhile to try 
SIT in selected cases of severe AD.
 In 1992, Glover and Atherton (40) published 
their results of a double-blind controlled trial of 
SIT in AD children sensitized to Dp allergens. 
A standard 8-month course of treatment with 
tyrosine-absorbed Dp vaccine on 24 AD children 
failed to demonstrate superiority over placebo. In 
the second phase, however, children initially ad-
ministered active treatment were randomly allo-
cated to continue with active treatment or switched 
to placebo for further 6 months. The clinical scores 
suggested that prolonged hyposensitization may 
be more effective than placebo and further studies 
would be justiﬁed.
 In 1993, Leroy et al. (41), in a double blind pla-
cebo controlled study (DBPC), treated 24 adults 
with AD and allergic to Dp with intradermal injec-
tions of complexes containing autologous spe-
ciﬁc antibodies and Dp allergens. After 4 months 
of treatment, the placebo group received active 
therapy for further 8 months. The authors reported 
improvement after 4 months of treatment only in 
the active treated group. After 1 year of therapy, 
82% of the patients showed a mean improvement 
of 83%. Although the authors concluded that treat-
ment with allergen-antibody complexes was safe 
and effective for patients with AD, this method is 
not often used due to methodological and ﬁnancial 
difﬁculties.
 Also in 1993, Mosca et al. (42) published their 
data on the treatment of 41 patients with moderate 
to severe AD and respiratory symptoms with con-
ventional SIT and 48 patients with sub-lingual SIT 
(SLIT). All enrolled patients had been responding 
poorly to conventional methods of AD treatment. 
The observation period lasted for 3 years, and 
75.6% of the patients treated with SIT showed a 
signiﬁcant improvement, while 19.5% had side ef-
fects. SLIT treated patients improved signiﬁcantly 
in 64.4% of the cases, with a prevalence of side 
effects in 14.6%.
 In 1994, Pacor et al. (43) investigated 32 AD 
patients allergic to house dust mite allergens. SIT 
was performed for 3 years with appropriate al-
lergy vaccines (Bayropharm). Signiﬁcant clinical 
efﬁcacy was detected in all investigated patients. 
In addition, a general tendency of skin prick test 
negativization as well as a decrease in IgE levels 
was observed. 
 In 1994, Galli et al. (44) demonstrated in a 
group of 60 AD patients that oral SIT (Neo-Abel-
lo), although without side effects, is rather ineffec-
tive and does not affect the natural history of AD. 
Perhaps these contrasting results are dependent 
upon the different route - oral SIT -  which may be 
inadequate for AD patients.
 In 1996, Zwacka et al. (45) conducted a mul-
ticenter trial comparing different methods of 
Czarnecka-Operacz  and Silny     Acta Dermatovenerol Croat
Speciﬁc immunotherapy in atopic dermatitis   2006;14(1):52-59
ACTA DERMATOVENEROLOGICA CROATICA 55
treatment on 212 patients with AD. One group was 
treated with SIT, one with SLIT and another with 
conventional methods. To evaluate the efﬁcacy of 
the treatment, total serum concentrations of IgE 
and clinical status were compared at the second 
year of therapy with values obtained before treat-
ment. Signiﬁcant clinical improvement and a re-
duction of total IgE were noted in both the SIT and 
SLIT groups, with no signiﬁcant differences in the 
symptomatic drug-treated group of patients.
 Some Polish authors also approached the 
problem of SIT in AD. Rudzki et al. (46) conducted 
SIT in a group of 15 patients allergic to house dust 
mite allergens as well as Samochocki and Rudz-
ki (47) in a group of 6 patients sensitized to the 
mentioned aeroallergens. The authors were able 
to conﬁrm the good efﬁcacy of SIT in AD in most 
of the investigated cases. Troﬁmowicz et al. (48) 
were also able to prove the good efﬁcacy of SIT in 
a 3-year treatment of 22 AD patients.  Other au-
thors were also optimistic about this type of treat-
ment in selected cases of AD and published their 
data on this topic (49).  
 Regardless of all the studies and publications, 
SIT in the treatment of AD remains a controver-
sial problem. A WHO position paper (50) clearly 
states that immunotherapy for AD is accepted only 
for clinical trials, as two DBPC trials have been 
evaluated exclusively (40,41). As we have just 
presented, there were at least ﬁve such trials, and 
such studies are not ideal from clinical and ethical 
standpoints. The necessity of DBPC trials in eval-
uating the efﬁcacy of SIT appears to be directly 
borrowed from that of other drug investigations. A 
DBPC randomised study design gives rise to evi-
dence of the highest grade as to the safety and ef-
ﬁcacy of a drug that by deﬁnition exerts its action 
in a short time and is poorly inﬂuenced by con-
foundings. The biological effects of SIT in terms of 
antiallergic and anti-inﬂammatory modes of action 
obviously require a long time period to be recog-
nised, and well-designed observational studies 
should also be considered for ﬁnal conclusions. 
Otherwise, the under-valuation of this therapeutic 
approach is certain.
 In our Department of Dermatology and Aller-
gic Diseases Diagnostic Center, SIT is being per-
formed in over 113 AD patients, and our observa-
tions of its clinical efﬁcacy and safety are promis-
ing. We have performed a 48-month observational 
study (51) followed by a DBPC trial (12 months) 
(results in press).  
 The basic aim of the observational study was 
to evaluate the efﬁcacy of speciﬁc immunotherapy 
performed with Novo-Helisen Depot allergy vac-
cines in a group of 37 patients with AD, allergic 
to house dust mites (n-14), grass pollen allergens 
(n-17) or grass pollen and mugwort pollen aller-
gens (n-6). IgE-mediated airborne allergy was 
conﬁrmed in all cases, and SIT was performed 
with allergy vaccines of appropriate composition: 
Dermatophagoides pteronyssinus 50%, Derma-
tophagoides farinae 50%, grass pollen allergens 
100%, grass pollen allergens 80% and mugwort 
pollen allergens 20%. The control group consisted 
of 29 patients with AD and conﬁrmed IgE-mediat-
ed allergy to analogous airborne allergens (house 
dust mites – 14 patients, grass pollen allergens 
– 11 cases, grass pollen and mugwort pollen aller-
gens – 4 cases). In the control group, conventional 
methods of treatment of AD were applied, i.e. anti-
histaminic drugs, antiinﬂammatory and antipruritic 
medications or topical glucocorticosteroids. 
 Patients recruited for the SIT and control 
groups presented similar clinical scores and simi-
lar allergological and immunological status. A clini-
cal evaluation of the severity and extensiveness 
of skin inﬂammation in AD patients was performed 
using the W-AZS index before treatment and after 
12, 24, 36, and 48 months of therapy. The clini-
cal efﬁcacy of SIT and conventional methods was 
evaluated according to W-AZS values during the 
course of therapy.  SIT was found to be an effec-
tive method of treatment of selected patients with 
AD and IgE-mediated airborne allergy. The efﬁ-
cacy of this therapeutic method was signiﬁcantly 
higher than the efﬁcacy of conventional methods 
applied in the control group in all 3 age compart-
ments analyzed and in cases of patients allergic 
to house dust mites, grass pollen and mugwort 
pollen allergens. In the group of patients treated 
with Novo-Helisen Depot vaccines, asymptomatic 
status was observed after 48 months of therapy in 
12 cases (32.4%), signiﬁcant improvement in 21 
patients (56.8%), improvement in 2 cases (5.4%) 
and no improvement or slight improvement in 2 
patients (5.4%). In the control group, asymptomat-
ic status was registered in 2 cases (6.9%), signiﬁ-
cant improvement in 9 patients (31.0%), improve-
ment in 10 cases (34.5%) and no improvement in 
8 patients (27.6%). 
 Comparative assessment of the clinical efﬁca-
cy of both therapeutic approaches revealed a sig-
niﬁcant difference to the advantage of SIT after 12 
months (p<0.05), 24 months (p<0.001), 36 months 
(p<0.001) and 48 months (p<0.001) of treatment. 
It seems that the effectiveness of SIT is related to 
the proper selection of patients and the adequacy 
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of vaccines, and detailed clinical evaluation and 
proper allergological diagnostic are therefore nec-
essary. SIT appeared to be a safe method of treat-
ment, and the development of allergic respiratory 
symptoms was found relatively rarely in compari-
son to the control group. 
 There were signiﬁcant differences between the 
group of patients treated with allergy vaccines and 
the control group in the results of allergological 
and immunological investigations (skin prick tests, 
serum levels of total IgE, asIgE, ECP, IL-4, IL-5, 
IL-10, IFN-γ, sIL-2R). In the SIT group, the nega-
tivization of skin prick tests, a decrease in the se-
rum level of total IgE (directed against respective 
allergens), ECP (p<0.001) and sIL-2R (p<0.01) 
were noticed after 48 months of therapy. On the 
contrary, in the control group there were no ten-
dency for the negativization of skin prick tests, and 
we observed an increase of serum levels of total 
IgE, asIgE, IL-4 (p<0.01) and IL-5 (p<0.05) after 
48 months of therapy. 
 No signiﬁcant correlation of serum cytokine 
concentrations with clinical status of patients was 
shown. There was also no correlation of skin prick 
test results with serum asIgE levels, but signiﬁcant 
correlations of serum concentrations of asIgE for 
house dust mites and grass pollen allergens (in 
appropriate groups of allergens) were noticed. It 
therefore seems that allergological diagnostic in 
patients suffering from atopic dermatitis should 
consist not only of skin prick tests but should also 
include an evaluation of serum asIgE directed 
against main suspected allergens. This is espe-
cially important when SIT is planned for the treat-
ment of patients. 
 In our DBPC trial, SIT was performed for 12 
months. Twenty patients with AD and monovalent 







DBPC 26 SC 2 years + Kaufman HS
1974   (33)
OBSERVATION 15 SC 12  
months
+ Di Prisco de Fuenmayor
1979   (34)
DBPC 2 SC 2 years + Ring J
1982   (38)




OBSERVATION 15 SC 12  
months
+ Rudzki
1990   (46)
DBPC 24 SC 8+6
months
+/- Glover MT
1992   (40)
DBPC 24 ID 4+8
months
+ Leroy BP
1993   (41)
OBSERVATION 41 SC/SL 3 years + Mosca M
1993   (42)
OBSERVATION 32 SC 3 years + Pacor ML
1994   (43)
OBSERVATION 60 ORAL 3 years - Galli E
1994   (44)
OBSERVATION 32 SC 3 years + Troﬁmowicz A
1995   (48)
OBSERVATION 212 SC/SL 2 years + Zwacka G
1996   (45)
OBSERVATION 35 SL 2+4 years + Mastrandrea F
2000   (49)
OBSERVATION 37 SC 4 years + Czarnecka-Operacz M
2000   (51)
DBPC 20 SC 12  
months
+ Silny W
2003   (55)
OBSERVATION 36 SC 36
months
+ Silny W
2005   (52,53,54)
Table 1. Main trials performed on SIT in AD
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airborne allergy (house dust mites or grass pol-
lens) were enrolled in the study (age: 5-40 years). 
SIT was performed with Novo-Helisen Depot al-
lergy vaccines prepared for the controlled condi-
tions by the Nexter-Allergopharma pharmaceuti-
cal company. We evaluated the clinical efﬁcacy of 
the treatment based upon the W-AZS index, and 
we measured the serum concentration of total IgE 
asIgE and other selected immunological parame-
ters (ECP, sIL-2R, IFN-γ, IL-4, IL-5, IL-10). Before 
treatment, the mean value of the W-AZS index was 
87.6±15.8 pts. in the SIT group and decreased 
to 38.8±34.4 pts. after 12 months of therapy ( 
p<0.01). In the placebo group, the mean value of 
the W-AZS index was 86.3±15.7 pts. before treat-
ment, and after 12 months of therapy it increased 
to 111.9±41.7 pts. Comparative statistical analysis 
indicated a signiﬁcant difference between the two 
investigated groups to the advantage of patients 
treated with active allergy vaccines (p<0.01). Se-
rum levels of asIgE in the SIT group showed a 
clear tendency to decrease, although we were not 
able to indicate the statistical signiﬁcance of this 
phenomenon due to the small size of the investi-
gated population. On the contrary, the concentra-
tion of asIgE serum in the placebo group tended 
to increase.  We also monitored serum concentra-
tions of selected immunological parameters (ECP, 
sIL-2R, IFN-γ, IL-4, IL-5, IL-10). 
  In conclusion speciﬁc immunotherapy is an ef-
fective method of treatment in selected cases of 
atopic dermatitis patients with well documented 
IgE-mediated airborne allergy. It seems to be 
strongly beneﬁcial in the case of children and teen-
agers (52) in terms of clinical picture and modiﬁca-
tion of the natural course of atopic march.
 We have listed the main trials performed on SIT 
in AD in Table 1.
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